CAR T Cell Therapy for Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (1 March 2024) | Viewed by 27733
Special Issue Editor
Special Issue Information
Dear Colleagues,
Chimeric antigen receptors (CARs) endow T cells with antigen-specific recognition, activation, and proliferation independent of major histocompatibility complex. Successful treatment of hematologic malignancies with CD19-CAR T cells was a milestone for this approach. However, an enduring antitumor response is still absent in most patients, as they succumb to either CD19+ or CD19− tumor relapse in the long term. Furthermore, treatment success has been hampered in patients with solid tumors. These therapies are currently limited in part by a lack of persistence and expansion of the transplanted T cells. In addition, response is highly variable among individuals. CAR T cells have not only demonstrated profound potency but also severe toxicity from “on-target/off-tumor” effects. In this Special Issue, we invite authors to submit high-quality original research and review articles that advance our understanding of CAR T-cell therapies with a focus on one or several of the following topics: cellular engineering, hematologic malignancies, solid tumors, efficacy, toxicity, safety, combinatorial approaches, antigen escape, trafficking, microenvironment, mechanisms, exhaustion, targets, allogeneic/off-the-shelf approaches, manufacturing, regulation, and biomarkers.
Dr. Simone Krebs
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR T cells
- cellular engineering
- hematologic malignancies
- solid tumors
- toxicity
- combinatorial approaches
- antigen escape
- microenvironment
- allogeneic/off-the-shelf
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.